Q3 2017 Earnings Forecast for Valeant Pharmaceuticals Intl Inc Issued By Jefferies Group (VRX)
Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) – Equities researchers at Jefferies Group dropped their Q3 2017 earnings per share estimates for Valeant Pharmaceuticals Intl in a research note issued on Wednesday. Jefferies Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will post earnings per share of $1.05 for the quarter, down from their previous estimate of $1.38. Jefferies Group also issued estimates for Valeant Pharmaceuticals Intl’s Q4 2017 earnings at $1.01 EPS, FY2017 earnings at $4.37 EPS, FY2018 earnings at $4.22 EPS, FY2019 earnings at $4.88 EPS, FY2020 earnings at $5.69 EPS and FY2021 earnings at $6.47 EPS.
VRX has been the subject of a number of other research reports. Royal Bank Of Canada reissued an “outperform” rating on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, April 18th. TD Securities increased their price objective on Valeant Pharmaceuticals Intl to C$26.00 and gave the company a “hold” rating in a research note on Wednesday, July 12th. Scotiabank dropped their price objective on Valeant Pharmaceuticals Intl to C$16.00 and set a “sector perform” rating for the company in a research note on Wednesday, April 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, June 29th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Valeant Pharmaceuticals Intl presently has an average rating of “Hold” and a consensus target price of C$23.33.
WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/q3-2017-earnings-forecast-for-valeant-pharmaceuticals-intl-inc-issued-by-jefferies-group-vrx/1471570.html.
Valeant Pharmaceuticals Intl (TSE VRX) opened at 17.57 on Friday. Valeant Pharmaceuticals Intl has a 12 month low of $11.20 and a 12 month high of $42.25. The stock has a 50 day moving average of $21.24 and a 200-day moving average of $17.60. The firm’s market cap is $6.11 billion.
In other news, Director John Paulson sold 24,700 shares of the stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of C$14.66, for a total transaction of C$362,102.00.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex.
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.